How Tirzepatide Works: GLP-1 and GIP, Explained

TL;DR

• Tirzepatide activates GIP and GLP-1 receptors, so “dual” means one molecule engages two signaling routes rather than two medicines being mixed together.¹
• In a Chinese phase 3 trial, tirzepatide groups had larger HbA1c and body-weight reductions than placebo, with gastrointestinal events the most common treatment-emergent problems.²
• Receptor-gene variants may help explain differences in signaling, response, or some adverse events, but prospective studies are still needed for clinical use.³
• Mouse and cell studies can suggest downstream pathways, but their preclinical findings do not establish the same direct effects in Filipino patients.⁴

In the Philippines, health talk can move fast. A name heard in a clinic may soon appear in a family group chat or online post. Tirzepatide is often called a “dual agonist,” but that phrase needs unpacking.¹ It describes action at two hormone receptors, not two medicines in one package.¹ It also does not predict what will happen to an individual person.¹³

Begin with the two receptor signals

Scientific reviews describe tirzepatide as an agonist at the GIP and GLP-1 receptors.¹ An agonist activates a receptor and starts signals inside cells.¹ Here, “dual” means that one molecule engages both receptor systems.¹ It does not mean two active medicines were simply blended together in one package.¹

Clinical studies then measure results from that combined activity.² Common outcomes include glycated hemoglobin, body weight, and adverse events.² Researchers observe the integrated result in a person, not either receptor working alone.¹² The phrase “GIP plus GLP-1” is therefore a useful starting point.¹ It is not a full map of every later biological step.¹

For a neutral catalog reference to the molecule discussed above, see the tirzepatide card.

What one human phase 3 trial found

A phase 3 study enrolled 206 Chinese adults with early type 2 diabetes.² Participants were randomly assigned to tirzepatide groups or placebo for 40 weeks.² Every active-treatment group had a larger average HbA1c reduction than placebo.² Average body-weight reductions were also larger in the active groups.²

Gastrointestinal problems were the most common treatment-emergent adverse events in those groups.² Investigators reported no clinically significant or severe hypoglycemia in this specific trial.² These findings come from people, but the setting matters.² Participants lived in China, had early type 2 diabetes, and followed a controlled study plan.² Those group averages are not personal forecasts for Filipino readers.²³

Why dual action is not simple arithmetic

The human trial tested the full molecule rather than each receptor pathway on its own.¹² It cannot show that GIP produced one fixed percentage of the outcome.² It also cannot assign the remaining percentage to GLP-1.² Researchers instead see the result after both systems are activated.¹

A 2026 review adds another layer: receptor genes can vary among people.³ The authors linked some GLP1R and GIPR variants with signaling, clinical response, or nausea and vomiting risk.³ They also said prospective studies are needed before these findings become clinically actionable.³ The review discussed several populations but did not establish a Filipino genetic response profile.³ Dual action names a mechanism; it is not an individual-results calculator.¹³

Appetite and energy: clues from a preprint

One preprint paired a human observation with experiments in mice fed to develop obesity.⁵ In the human data, baseline leptin levels correlated with later weight-loss response.⁵ A correlation does not show that leptin caused the response.⁵ The mouse experiments then studied tirzepatide together with leptin.⁵

In those mice, the combination had larger effects on food intake and energy expenditure.⁵ Researchers also reported changes in insulin sensitivity and hypothalamic neuron signaling.⁵ These findings offer clues about brain circuits and energy balance.⁵ Yet they remain preprint and animal evidence.⁵ They do not establish the same combination effect in people.⁵ They also cannot explain every human weight change.⁵

Beyond weight: plausible is not proven

Another preprint studied wire-injured arteries in mice and cultured human endothelial cells.⁴ Tirzepatide affected arterial remodeling in the mouse experiments.⁴ It also increased nitric oxide production in the cultured cells.⁴ Blocking nitric oxide synthesis removed one reported protective effect in mice.⁴ This is preclinical evidence, not proof of a direct vascular effect in people.⁴

A separate review examined obesity-related obstructive sleep apnea.⁶ It discussed inflammation, insulin sensitivity, adipokines, autonomic regulation, and breathing control.⁶ However, the review could not separate weight-related effects from effects independent of weight.⁶ Several pathways may be biologically plausible, while direct weight-independent effects in humans remain unsettled.⁴⁶

Body weight does not describe every tissue

Scale weight combines fat, lean tissue, water, and other components.⁷ A phase 2 trial explored body composition in 102 adults with overweight or obesity.⁷ Both groups received tirzepatide.⁷ One group also received apitegromab, while the other received placebo.⁷

At 24 weeks, the apitegromab group preserved more lean mass.⁷ Total body-weight loss was similar between the groups.⁷ This result does not show that dual incretin activity preserved lean tissue.⁷ It shows that an experimental myostatin-targeting medicine changed body composition in a combination study.⁷ Because both groups received tirzepatide, the trial cannot identify each incretin receptor’s contribution.¹⁷ Total weight and tissue composition are related but separate outcomes.⁷

For a neutral catalog reference to the single-receptor comparator named in the supplied research, see the semaglutide card.

Maintenance results answer a different question

The phase 3b SURMOUNT-MAINTAIN trial began with a weight-loss period in US adults with obesity.⁸ Eligible participants then continued treatment, moved to a lower amount, or switched to placebo.⁸ At week 112, continued treatment maintained more prior weight reduction than switching to placebo.⁸

Gastrointestinal events were again the most common adverse events.⁸ They were mostly mild to moderate in this study.⁸ This result describes what happened after continuation or withdrawal under trial conditions.⁸ It does not reveal the separate contribution of either receptor.¹⁸ The US study also used eligibility rules, so its averages are not personal forecasts for Filipino readers.⁸ Mechanism and treatment course answer different research questions.¹⁸

Product names, records, and formulations

US FDA records identify Mounjaro and Zepbound as named tirzepatide autoinjector products.⁹¹⁰ They sit under separate US applications.⁹¹⁰ The records show original approvals in 2022 and 2023, respectively.⁹¹⁰ Each record applies to the named regulated product and indication.⁹¹⁰

Formulation is another question.¹¹ An editorial survey found 33 compounded semaglutide or tirzepatide products on websites searched in 2025.¹¹ The products varied in route, formulation, or added ingredients.¹¹ Reporting of storage and beyond-use details was limited.¹¹ The authors described efficacy and safety as largely unknown.¹¹ The survey did not laboratory-test every compounded product.¹¹ Receptor biology, regulatory identity, and product equivalence are separate layers.¹⁹¹¹

Bottom line

Tirzepatide is one molecule that activates both GIP and GLP-1 receptors.¹ Human trials show changes in HbA1c and body weight in defined populations.²⁸ Gastrointestinal events appear repeatedly in the supplied clinical evidence.²⁸ Those trials do not split outcomes neatly between the two receptors.¹² Reviews, animal experiments, cell studies, and combination trials add possible detail.⁵⁴⁷ Their study contexts must stay attached to the findings.⁵⁴⁷ For Filipino readers, “dual agonist” is best treated as a precise receptor-level description.¹ It is not a promise, a personal forecast, or proof that every similarly named product is equivalent.¹⁹¹¹

Frequently asked questions

Is tirzepatide a combination of two medicines?

No. The reviewed literature describes one molecule that activates the GIP and GLP-1 receptors.¹ “Combination” in this explainer refers to dual receptor activity.¹ It does not mean two separately packaged active medicines were blended together.¹ The human studies measure the integrated molecule.²

Does GIP do half the work and GLP-1 the other half?

The supplied human trials do not assign fixed percentages to each receptor.¹² They test the complete molecule and observe the combined result.² An exact split would go beyond those findings.² “Dual” identifies two receptor targets, not two equal shares.¹

What do human studies establish most clearly?

A Chinese phase 3 trial found larger HbA1c and body-weight reductions with tirzepatide than placebo over 40 weeks.² A US maintenance trial found more prior weight reduction was maintained with continued treatment than after switching to placebo.⁸ Each finding belongs to its own population and protocol.²⁸

Are all proposed mechanisms proven in people?

No. Leptin and neuron findings came mainly from mice in a preprint.⁵ Nitric oxide findings came from mice and cultured cells in another preprint.⁴ These studies can generate useful hypotheses.⁵⁴ They cannot prove the same causal pathways in humans.⁵⁴

Are outcomes the same for everyone?

Human responses vary.³ A review suggests that GLP1R and GIPR gene variants may affect signaling, outcomes, and some adverse-event risk.³ Prospective evidence is still needed before this becomes clinically actionable.³ The review did not establish a Filipino-specific genetic response profile.³

Does a US record apply to any item called tirzepatide?

No. The FDA records cited here cover the named US-regulated Mounjaro and Zepbound products.⁹¹⁰ They also cover specific applications and indications.⁹¹⁰ A record for one named product does not establish equivalence for another item using the ingredient name.⁹¹⁰

How should readers judge comparison findings?

First check whether the evidence is a direct human trial, an indirect comparison, or preclinical work.¹²⁵⁴ A network meta-analysis compares patterns across trials.¹² Not every included medicine had a direct head-to-head study.¹² Study type sets the limits.¹²

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Sources

Footnotes

1. Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹ ↩²² ↩²³ ↩²⁴ ↩²⁵ ↩²⁶ ↩²⁷

2. Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹ ↩²² ↩²³ ↩²⁴ ↩²⁵

3. Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

4. Tirzepatide Attenuates Wire Injury-Induced Arterial Remodeling in Non-Diabetic and Diabetic Mice: Comparison with Semaglutide. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

5. Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶

6. Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?. ↩ ↩² ↩³ ↩⁴

7. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

8. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

9. FDA Drugs@FDA record for ZEPBOUND (TIRZEPATIDE). ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

10. FDA Drugs@FDA record for MOUNJARO (TIRZEPATIDE). ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

11. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

12. Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.. ↩ ↩² ↩³ ↩⁴